NCT00760981 - A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Graft vs Host Disease

Interventions

DRUG

Imatinib

The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.

Trial Locations (2)

Stanford University School of Medicine, Stanford

Fred Hutchinson Cancer Research Center (FHCRC), Seattle